LivaNova PLC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vladimir A. Makatsaria
- Full Time Employees
- 3,300
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 5220 Valiant Court London GL United Kingdom GL3 4FE
- IPO Date
- Oct 19, 2015
- CIK
- 0001639691
- Website
- livanova.com
- Similar Companies
- Business
- LivaNova PLC (Nasdaq: LIVN) develops and markets medical devices focused on cardiopulmonary surgery and neuromodulation therapies for neurological and psychiatric disorders. The company offers a comprehensive portfolio including the Essenz heart-lung machine platform and related perfusion systems, high-performance oxygenators for adult and pediatric patients, autotransfusion systems, cannulae, perfusion tubing disposables; and the VNS Therapy system providing vagus nerve stimulation for drug-resistant epilepsy, difficult-to-treat depression and obstructive sleep apnea, alongside the aura6000 system for proximal hypoglossal nerve stimulation. LivaNova operates globally in over 100 countries with manufacturing sites in Italy, the United States and Canada; it was formed in 2015 through the merger of Sorin SpA and Cyberonics Inc. and maintains headquarters in London, UK. Recent developments include raising full-year 2025 revenue growth guidance to 8.5%-9.5% constant currency following Q3 2025 results that showed 12.5% organic revenue growth driven by Essenz sales and cardiopulmonary consumables; unveiling a 2030 strategic roadmap targeting high-single-digit-plus revenue CAGR, adjusted operating margins in the high-twenties and an independent US commercial launch for obstructive sleep apnea therapy in 2027; securing CMS reimbursement enhancements effective January 2026 that boost hospital payments for VNS Therapy implants by approximately 48%; initiating Essenz commercial launch in China; appointing Lucile Blaise as Global Head of Commercialization for Obstructive Sleep Apnea and Donald Zurbay to the Board of Directors in late 2025; and presenting long-term real-world data at medical conferences demonstrating up to 95% median seizure reductions with VNS Therapy at 36 months alongside health economics benefits including reduced hospitalizations.
Company News
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
LivaNova Q3 Earnings Call Highlights
LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
LivaNova PLC $LIVN Shares Newly Acquired by Avidian Wealth Enterprises LLC
Squarepoint Ops LLC Acquires Shares of 17,242 LivaNova PLC $LIVN
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LivaNova Director Sells 1,650 Shares for $131,500
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE
Dynatronics (NASDAQ:DYNT) vs. LivaNova (NASDAQ:LIVN) Critical Review
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova Q2 Earnings Call Highlights
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Amundi Cuts Stock Position in LivaNova PLC $LIVN